We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

155 hedge funds and large institutions have $703M invested in Akebia Therapeutics in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 54 increasing their positions, 42 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

676% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $1.4M

32% more capital invested

Capital invested by funds: $532M → $703M (+$171M)

29% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 42

23% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 22

1% more funds holding

Funds holding: 153 → 155 (+2)

0.62% more ownership

Funds ownership: 70.83% → 71.45% (+0.62%)

Holders
155
Holders Change
+2
Holders Change %
+1.31%
% of All Funds
3.42%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
27
Increased
54
Reduced
42
Closed
22
Calls
$10.9M
Puts
$1.4M
Net Calls
+$9.48M
Net Calls Change
+$6.58M

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$55.4M
2
FCM
Farallon Capital Management
California
+$9.72M
3
Invesco
Invesco
Georgia
+$8.83M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.7M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$6.45M

Top Sellers

Rank Fund Capital Flow
1
BG
Baupost Group
Massachusetts
-$15.9M
2
Morgan Stanley
Morgan Stanley
New York
-$6.29M
3
Citadel Advisors
Citadel Advisors
Florida
-$5.36M
4
WP
Woodline Partners
California
-$5.03M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
LC
151
Lindbrook Capital
California
$1K +$724 +93 New
EI
152
Ellevest Inc
New York
$1K +$794 +102 New
DI
153
Disciplined Investments
Oklahoma
$1K +$1.46K +187 New
LCC
154
Lincoln Capital Corp
Rhode Island
$180 – – –
Renaissance Technologies
155
Renaissance Technologies
New York
– -$875K -138,527 Closed
First Manhattan
156
First Manhattan
New York
– -$783K -123,900 Closed
IA
157
IndexIQ Advisors
New York
– -$626K -99,038 Closed
BGIM
158
Brandywine Global Investment Management
Pennsylvania
– -$570K -89,760 Closed
JIC
159
Johnson Investment Counsel
Ohio
– -$481K -76,141 Closed
Allianz Asset Management
160
Allianz Asset Management
Germany
– -$376K -59,431 Closed
Rafferty Asset Management
161
Rafferty Asset Management
New York
– -$361K -57,128 Closed
WG
162
Winton Group
United Kingdom
– -$239K -37,812 Closed
TSS
163
Two Sigma Securities
New York
– -$194K -30,694 Closed
FIA
164
FNY Investment Advisers
New York
– -$94K -15,000 Closed
B
165
Bailard
California
– -$94K -14,900 Closed
Prudential Financial
166
Prudential Financial
New Jersey
– -$81K -12,760 Closed
Assenagon Asset Management
167
Assenagon Asset Management
Luxembourg
– -$77K -12,146 Closed
FC
168
Fusion Capital
South Carolina
– -$67K -10,561 Closed
QT
169
Quantbot Technologies
New York
– -$27K -4,300 Closed
RFM
170
Royal Fund Management
Florida
– -$12K -2,000 Closed
ACM
171
Allred Capital Management
Texas
– -$4.25K -673 Closed
EW
172
Evoke Wealth
California
– -$3.63K -575 Closed
BCWM
173
Bartlett & Co Wealth Management
Ohio
– -$3.29K -500 Closed
PWMG
174
Prestige Wealth Management Group
New Jersey
– -$3K -500 Closed
PNC Financial Services Group
175
PNC Financial Services Group
Pennsylvania
– -$1K -110 Closed
3 4 5 6
7

AKBA Hedge Fund Activity: Q1 2020 in Review

155 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2020, worth a combined $703M — up 32% from $532M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AKBA positions and 22 closed out — a net gain of 5 holders — while 54 added to existing stakes and 42 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $55.4M. The largest seller was Baupost Group, cutting an estimated $15.9M.

  • 155 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2020, up from 153 in Q4 2019.
  • Funds reported $703M of Akebia Therapeutics stock for Q1 2020, up 32% quarter-over-quarter.
  • 27 funds opened new Akebia Therapeutics positions in Q1 2020 and 22 closed out, a net change of +5 holders.
  • The largest Akebia Therapeutics buyer in Q1 2020 was Consonance Capital Management, an estimated $55.4M added.
  • The largest Akebia Therapeutics seller in Q1 2020 was Baupost Group, an estimated $15.9M sold.

Based on aggregated 13F filings for Q1 2020.